Terbinafine is a synthetic antifungal compound and is an allylamine derivative. it acts by inhibtion of squalene epoxidase in fungal cell membrane.
Fungal infections of the skin caused by dermatophytes like Trichophyton spp., Microsporum spp., Epidermophyton spp. Orally indicated in the treatment of onychomycosis caused by dermatophytes
Adults: 250mg for a duration of 2-6 weeks in Tinea pedia, 2-4 weeks in Tinea corporis/curis, 2-4 weeks in candidiasis, 4 weeks Tinea capitis. 6-12 weeks in onychomycosis
Children: 2 yrs. and old: upto 20kg bodywieght and above): 62.5mg once a day; 20 to 40kg body weight: 125mg once a day;> 40kg bodyweight:250mg once a day
Hypersenstivity to terbinafine
Pre-existing liver or renal impairment, irregular use or premature discontinuation carries the risk of recurrence of infection. Elderly patients, pregnancy lactation
Gastrointestinal symptoms, skin reactions, taste disturbance, hepatbiliary dysfuction, haematological disorders
Negligible potential for inhibiting or inducing the clearance of drugs that are metabolised via cytochrome system e.g. cyclosporin, tolbutamide or oral contraceptives. Drugs that induce or inhibit microsomal enzymes may interfere with terbinafine metabolism. Terbinafine decreases caffeine clearance